$TEM News

Tempus AI Got an $80 Target and 28% Upside Call. Is Wall Street Underestimating Its Healthcare Data Moat?

Tempus AI's Data Business Is Priced Like a Vendor, Not a Platform, Analyst Says

Cantor Fitzgerald Initiates Coverage On Tempus AI with Overweight Rating, Announces Price Target of $80

Piper Sandler Lifts Tempus AI to Overweight at $76

Piper Sandler Upgrades Tempus AI to Overweight, Raises Price Target to $76

Freedom Capital Markets Maintains Hold on Tempus AI, Raises Price Target to $73

Tempus AI (TEM) Jumped on Moderna’s Melanoma Win. Did its $1.5B Personalis Acquisition Just Get Validated?

Tempus AI (TEM) Wins FDA Clearance For ECG Tool That Flags Pulmonary Hypertension

Tempus AI Receives FDA Clearance For Tempus ECG-PH For Signs Associated With Pulmonary Hypertension

Tempus AI: Winning With Precision Medicine

Tempus AI Stock Climbs Friday: What's Driving the Move?

Why Is Tempus AI Stock Gaining Thursday?

BTIG Maintains Buy on Tempus AI, Raises Price Target to $80

Tempus AI Soars as Merck-Moderna Cancer Trial Validates Personalis Acquisition

Tempus AI: The Data Flywheel Has Started Spinning

CellCarta To Include Tempus In CDx Commercialization Lab Network As Network's Second Commercial Laboratory Partner, Enhancing Oncology Companion Diagnostics For Biopharma

Piper Sandler Maintains Neutral on Tempus AI, Lowers Price Target to $56

Tempus AI Announces Publication Of Study Results In 'Nature Medicine' That Demonstrate The PRISM2 Pathology Foundation Model's Ability To Perform Clinically Important Diagnostic Tasks

BTIG Maintains Buy on Tempus AI, Lowers Price Target to $70

HC Wainwright & Co. Maintains Buy on Tempus AI, Lowers Price Target to $56